Eli Lilly said on Thursday a late-stage trial showed its weight-loss drug Zepbound, used with its psoriatic arthritis ...

In an open-label phase 3b trial, the co-administration of Lilly’s IL-17A antagonist Taltz (ixekizumab) and dual GIP/GLP-1 ...

Eli Lilly will buy autoimmune drug developer Ventyx Biosciences for $1.2 billion in cash, the companies said on Wednesday, ...

Patients given a combination of Eli Lilly & Co.’s weight-loss shot Zepbound and arthritis drug Taltz saw a greater ...

Evangeline Lilly didn’t ease into 2026 with a vague caption or a polished PR statement. Instead, the Lost and Marvel star sat ...

It sounds like Lilly did just that. The U.S. pharma announced on Wednesday that it was paying $14 per share of Ventyx—more ...

Eli Lilly is in advanced talks to buy Ventyx Biosciences for more than $1 billion, the Wall Street Journal reported on ...

The buyout is a bet by Lilly on an increasingly popular drug target known as NLRP3 inflammasomes, which are implicated in an ...

Nimbus Therapeutics said on Tuesday it has entered into a multi-year research and licensing agreement with Eli Lilly to ...

Eli Lilly has dominated headlines in recent months, recently taking the crown as the most valuable company in the biopharma ...

Evangeline Lilly says she has brain damage, months after fainting and hitting her head on a rock while at the beach.

The 2026 Lilly Endowment Community Scholarship recipients for multiple Wabash Valley counties, have been announced by their ...